Q2 STOCKS TO BUY

Iovance Stock Eyes Best Day Since 2020 After FDA Nod

Shares are today trading at 52-week highs

Digital Content Manager
Feb 20, 2024 at 10:26 AM
facebook X logo linkedin


Iovance Biotherapeutics Inc (NASDAQ:IOVA) stock is up 39.5% at $12.76 at last check, after the company received accelerated approval from the Food and Drug Administration (FDA) for its cell therapy for adults with advanced melanoma, which is priced at $515,000 per patient. The biopharma name also priced its $211 million common stock offering at $9.15 per share.

Shares are today trading at 52-week highs, after bouncing off the 50-day moving average earlier this month. Iovance Biotherapeutics stock is also on track for its biggest single-day percentage since March 2020, and has added a whopping 145.9% in the last three months.

Overall options volume is already running at 16 times the intraday average, with 41,000 calls and 9,176 puts exchanged so far. The weekly 2/23 15-strike call is the most active contact, with new positions being opened there.

An unwinding of short interest could further boost the shares. Short interest rose 15.3% over the last two reporting periods, and the 41.98 million shares sold short now make up 17.6% of the security's available float, or more than one weeks' worth of pent-up buying power.

 

“Buy This Stock Now!” - Expert Who Called 11x On TSLA

He called a rare 11x on Tesla…

But now, thanks to Elon & Trump’s new alliance…

He says there’s a new opportunity that could be 1,000x BIGGER than Tesla – and it could completely revolutionize a $23 Trillion market.

It’s trading for less than $5 per share right now…

But it won’t be under the radar for long.

Discover The 1,000x Bigger Elon Opportunity Here